Data_Sheet_2_A Six-lncRNA Signature for Immunophenotype Prediction of Glioblastoma Multiforme.PDF (270.72 kB)
Download file

Data_Sheet_2_A Six-lncRNA Signature for Immunophenotype Prediction of Glioblastoma Multiforme.PDF

Download (270.72 kB)
dataset
posted on 13.01.2021, 05:33 by Ming Gao, Xinzhuang Wang, Dayong Han, Enzhou Lu, Jian Zhang, Cheng Zhang, Ligang Wang, Quan Yang, Qiuyi Jiang, Jianing Wu, Xin Chen, Shiguang Zhao

Glioblastoma multiforme (GBM) is the most aggressive primary tumor of the central nervous system. As biomedicine advances, the researcher has found the development of GBM is closely related to immunity. In this study, we evaluated the GBM tumor immunoreactivity and defined the Immune-High (IH) and Immune-Low (IL) immunophenotypes using transcriptome data from 144 tumors profiled by The Cancer Genome Atlas (TCGA) project based on the single-sample gene set enrichment analysis (ssGSEA) of five immune expression signatures (IFN-γ response, macrophages, lymphocyte infiltration, TGF-β response, and wound healing). Next, we identified six immunophenotype-related long non-coding RNA biomarkers (im-lncRNAs, USP30-AS1, HCP5, PSMB8-AS1, AL133264.2, LINC01684, and LINC01506) by employing a machine learning computational framework combining minimum redundancy maximum relevance algorithm (mRMR) and random forest model. Moreover, the expression level of identified im-lncRNAs was converted into an im-lncScore using the normalized principal component analysis. The im-lncScore showed a promising performance for distinguishing the GBM immunophenotypes with an area under the curve (AUC) of 0.928. Furthermore, the im-lncRNAs were also closely associated with the levels of tumor immune cell infiltration in GBM. In summary, the im-lncRNA signature had important clinical implications for tumor immunophenotyping and guiding immunotherapy in glioblastoma patients in future.

History